Gefitinib, an inhibitor of Epidermal growth factor receptor (EGFR) tyrosine kinase, suppresses allergic airway inflammation by inhibiting phosphatidyl inositol-3 kinase (PI3K)/Akt signaling in mouse model of asthma (Hur et al., 2007). Here, EGFR is linked to inflammation.